Cytrx Corporation Announces Key Addition to Corporate Development Team
March 01, 2018 at 09:00 am EST
CytRx Corporation announced the engagement of Eric L. Curtis, MBA, to provide strategic counsel for the Company's ongoing programs, including its LADR (Linker Activated Drug Release) technology platform and ultra-high potency drug candidates, beginning with proof of concept through clinical development. Most recently, he has provided commercial and strategic consultancy services to a variety of life science companies through his consultancy practice, Curtis Biopharm Consulting.